Search

Your search keyword '"Mirimanoff R"' showing total 281 results
Start Over Author "Mirimanoff R"
281 results on '"Mirimanoff R"'

1. Primary breast lymphoma

Author

Jeanneret Sozzi, W., Mirimanoff, R.-O., Belkacémi, Yazid, editor, Mirimanoff, René-Olivier, editor, and Ozsahin, Mahmut, editor

Published
2010
Full Text
View/download PDF

28. Duration of androgen suppression in the treatment of prostate cancer

Author

Bolla, M, de Reijke TM, Van Tienhoven, G, Van den Bergh AC, Oddens, J, Poortmans, Pm, Gez, E, Kil, P, Akdas, A, Soete, G, Kariakine, O, van der Steen Banasik EM, Musat, E, Piérart, M, Mauer, Me, Collette, L., EORTC Radiation Oncology Group, de Reijke TM, Genito Urinary Tract Cancer G. r. o. u. p., van Tienhoven, G, van den Bergh AC, van Andel, G, van de Beek, C, Schimmel, E, Descotes, Jl, Bosset, Jf, Hay, Mh, Bachaud, Jm, Maingon, P, Courdi, A, Barillot, I, Carrie, C, Rothe Thomas, F, Lekili, M, van Poppel, H, Vekemans, K, Van Houtte, P, Verbaeys, A, Hoekx, L, Cutajar, Cl, Mirimanoff, R, Magrini, Stefano Maria, Busetto, M, Bono, A, Villa, S, Arribas, L, Maldonado, X, Kynaston, H, Barber, J, Saxby, M, and Obralic, N.

Published
2009

29. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy

Author

Martinet, S., Ozsahin, M., Belkacemi, Y., Landman, C., Poortmans, P., Oehlere, C., Scandolaro, L., Krengli, Marco, Maingon, P., Miralbell, R., Studer, G., Chauvet, B., Marnitz, S., Zouhair, A., and Mirimanoff, R. O.

Subjects
Male, Analysis of Variance, Lymphoma, Non-Hodgkin, Age Factors, Radiotherapy Dosage, Middle Aged, Prognosis, Survival Rate, Treatment Outcome, Recurrence, Disease Progression, Humans, Orbital Neoplasms, Female, Aged, Neoplasm Staging
Abstract

To assess the outcome and prognostic factors in patients with orbital lymphoma treated by radiotherapy (RT).Between 1980 and 1999, 90 consecutive patients with primary orbital lymphoma were treated in 13 member institutions of the Rare Cancer Network. A full staging workup was completed in 56 patients. Seventy-eight patients had low-, 6 intermediate-, and 6 high-grade lymphoma, and 75 had a single orbital localization. All patients underwent RT with a median dose of 34.2 Gy (range 4.0-50.4). Eleven patients received chemotherapy in addition to RT.After RT, local control was achieved in 97% of the patients. Local progression occurred in 2% and local relapse 1%. The rate of systemic relapse was 20%, and 9% of the patients developed metachronous contralateral eye involvement. The 5-year disease-free survival, overall survival, and cause-specific survival rate was 65%, 78%, and 87%, respectively. In univariate analyses, the statistically significant favorable prognostic factors were younger age, low grade, normal erythrocyte sedimentation rate, absence of muscular infiltration, complete response to treatment, conjunctival localization, and normal lactate dehydrogenase value for overall survival, disease-free survival, and freedom from treatment failure. In multivariate analysis, the favorable factors were younger age and low grade for overall and disease-free survival; a favorable response, conjunctival localization, and complete staging were highly significant for disease-free survival and freedom from treatment failure. Neither the RT technique nor the total dose influenced the outcome. Cataract and xerophthalmia were the most prominent late toxicities.Moderate- to low-dose RT alone is able to control primary orbital lymphoma with low morbidity. A full staging workup is warranted in these patients. Prognostic factors were identified that could be useful in the overall management of this uncommon site of primary lymphoma.

Published
2003

30. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial

Author

Hegi, M E, Janzer, R C, Lambiv, W L, Gorlia, T, Kouwenhoven, M C M, Hartmann, C, von Deimling, A, Martinet, D, Besuchet Schmutz, N, Diserens, A C, Hamou, M F, Bady, P, Weller, M, van den Bent, M J, Mason, W P, Mirimanoff, R O, Stupp, R, Mokhtari, K, Wesseling, P, Hegi, M E, Janzer, R C, Lambiv, W L, Gorlia, T, Kouwenhoven, M C M, Hartmann, C, von Deimling, A, Martinet, D, Besuchet Schmutz, N, Diserens, A C, Hamou, M F, Bady, P, Weller, M, van den Bent, M J, Mason, W P, Mirimanoff, R O, Stupp, R, Mokhtari, K, and Wesseling, P

Abstract

Glioblastoma (GBM) is a morphologically heterogeneous tumor type with a median survival of only 15 months in clinical trial populations. However, survival varies greatly among patients. As part of a central pathology review, we addressed the question if patients with GBM displaying distinct morphologic features respond differently to combined chemo-radiotherapy with temozolomide. Morphologic features were systematically recorded for 360 cases with particular focus on the presence of an oligodendroglioma-like component and respective correlations with outcome and relevant molecular markers. GBM with an oligodendroglioma-like component (GBM-O) represented 15% of all confirmed GBM (52/339) and was not associated with a more favorable outcome. GBM-O encompassed a pathogenetically heterogeneous group, significantly enriched for IDH1 mutations (19 vs. 3%, p = 0.003) and EGFR amplifications (71 vs. 48%, p = 0.04) compared with other GBM, while co-deletion of 1p/19q was found in only one case and the MGMT methylation frequency was alike (47 vs. 46%). Expression profiles classified most of the GBM-O into two subtypes, 36% (5/14 evaluable) as proneural and 43% as classical GBM. The detection of pseudo-palisading necrosis (PPN) was associated with benefit from chemotherapy (p = 0.0002), while no such effect was present in the absence of PPN (p = 0.86). In the adjusted interaction model including clinical prognostic factors and MGMT status, PPN was borderline nonsignificant (p = 0.063). Taken together, recognition of an oligodendroglioma-like component in an otherwise classic GBM identifies a pathogenetically mixed group without prognostic significance. However, the presence of PPN may indicate biological features of clinical relevance for further improvement of therapy.

Published
2012

31. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study

Author

UCL - Autre, Mauer, Murielle E. L., Stupp, R., Taphoorn, M. J. B., Coens, Corneel, Osoba, David, Marosi, C., Wong, R., de Witte, O., Cairncross, J. G., Efficace, Fabio, Mirimanoff, R. O., Forsyth, P., van den Bent, M. J., Weller, M., Bottomley, Andrew, UCL - Autre, Mauer, Murielle E. L., Stupp, R., Taphoorn, M. J. B., Coens, Corneel, Osoba, David, Marosi, C., Wong, R., de Witte, O., Cairncross, J. G., Efficace, Fabio, Mirimanoff, R. O., Forsyth, P., van den Bent, M. J., Weller, M., and Bottomley, Andrew

Abstract

This is one of the few studies that have explored the value of baseline symptoms and health- related quality of life ( HRQOL) in predicting survival in brain cancer patients. Baseline HRQOL scores ( from the EORTC QLQ- C30 and the Brain Cancer Module ( BN 20)) were examined in 490 newly diagnosed glioblastoma cancer patients for the relationship with overall survival by using Cox proportional hazards regression models. Refined techniques as the bootstrap re-sampling procedure and the computation of C- indexes and R-2- coefficients were used to try and validate the model. Classical analysis controlled for major clinical prognostic factors selected cognitive functioning ( P= 0.0001), global health status ( P= 0.0055) and social functioning ( P < 0.0001) as statistically significant prognostic factors of survival. However, several issues question the validity of these findings. C- indexes and R-2- coefficients, which are measures of the predictive ability of the models, did not exhibit major improvements when adding selected or all HRQOL scores to clinical factors. While classical techniques lead to positive results, more refined analyses suggest that baseline HRQOL scores add relatively little to clinical factors to predict survival. These results may have implications for future use of HRQOL as a prognostic factor in cancer patients.

Published
2007

34. Corrigendum to: “Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy” [Eur J Cancer 2012;48(9): 1318–25]

Author

Van der Kwast, T., primary, Al Daoud, N., additional, Collette, L., additional, Sykes, J., additional, Thoms, J., additional, Milosevic, M., additional, Bristow, R.G., additional, Van Tienhoven, G., additional, Warde, P., additional, Mirimanoff, R.-O., additional, and Bolla, M., additional

Published
2012
Full Text
View/download PDF

36. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

Author

Weller, M., primary, Gorlia, T., additional, Cairncross, J. G., additional, van den Bent, M. J., additional, Mason, W., additional, Belanger, K., additional, Brandes, A. A., additional, Bogdahn, U., additional, Macdonald, D. R., additional, Forsyth, P., additional, Rossetti, A. O., additional, Lacombe, D., additional, Mirimanoff, R.- O., additional, Vecht, C. J., additional, and Stupp, R., additional

Published
2011
Full Text
View/download PDF

44. The EORTC QLQ-BN20 questionnaire for assessing the health-related quality of life (HRQoL) in brain cancer patients: A phase IV validation study on behalf of the EORTC QLG, BCG, ROG, NCIC-CTG

Author

Taphoorn, M. J., primary, Claassens, L., additional, Aaronson, N. K., additional, Coens, C., additional, Mauer, M., additional, Osoba, D., additional, Stupp, R., additional, Mirimanoff, R., additional, Van den Bent, M. J., additional, and Bottomley, A., additional

Published
2008
Full Text
View/download PDF

46. Is Long-Term Survival in Glioblastoma Possible? Updated Results of the EORTC/NCIC Phase III Randomized Trial on Radiotherapy (RT) and Concomitant and Adjuvant Temozolomide (TMZ) versus RT Alone

Author

Mirimanoff, R., primary, Mason, W., additional, Van den Bent, M., additional, Kortmann, R., additional, Taphoorn, M., additional, Brandes, A., additional, Villa, S., additional, Cairncrosss, G., additional, Gorlia, T., additional, and Stupp, R., additional

Published
2007
Full Text
View/download PDF

49. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study

Author

Mauer, M, primary, Stupp, R, additional, Taphoorn, M J B, additional, Coens, C, additional, Osoba, D, additional, Marosi, C, additional, Wong, R, additional, de Witte, O, additional, Cairncross, J G, additional, Efficace, F, additional, Mirimanoff, R O, additional, Forsyth, P, additional, van den Bent, M J, additional, Weller, M, additional, and Bottomley, A, additional

Published
2007
Full Text
View/download PDF

50. EORTC Study 26041–22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma—Results of a phase I trial

Author

Brandes, A. A., primary, Stupp, R., additional, Hau, P., additional, Sleijfer, S., additional, Lacombe, D., additional, Gorlia, T., additional, Yun, H., additional, Tosoni, A., additional, Mirimanoff, R., additional, and van den Bent, M. J., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results